While the NeoATP trial demonstrated the efficacy and safety of four cycles of pyrotinib and trastuzumab combined with weekly TCb neoadjuvant chemotherapy for patients with HER2‐positive locally advanced breast cancer, the study had a relatively small sample size. Here, ERBB2 is linked to breast carcinoma.